Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05679401 · ClinicalTrials.gov registry record · Phase 3

A Study With Imlifidase in Anti-GBM Disease

A Phase 3 study, sponsored by Hansa Biopharma AB.

Terminated
Registry status
Phase 3
Development phase
50
Enrollment target

NCT05679401: Clinical Trial Phase 3 study, sponsored by Hansa Biopharma AB.

NCT05679401 is a Phase 3 study that was terminated before completion, run by Hansa Biopharma AB. The registered enrollment target is 50 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05679401, a Phase 3 study, was terminated before completion, sponsored by Hansa Biopharma AB.

TERMINATED
Registry status
Phase 3
Development phase
50 participants
Enrollment target

Study Summary

An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.

Interventions

  • DRUG Glucocorticoids
  • DRUG Imlifidase
  • PROCEDURE Plasma exchange (PLEX)
  • DRUG Cyclophosphamide (CYC)

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-12-22
Est. Completion 2026-02-02
Phase Phase 3
Hansa Biopharma AB

7 total trials

Why NCT05679401 stopped before completion

NCT05679401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 4 interventions - of which Glucocorticoids is the first listed.

NCT05679401 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05679401 about?

NCT05679401 is a clinical study titled "A Study With Imlifidase in Anti-GBM Disease". An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.

What is the current status of trial NCT05679401?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2022-12-22. Estimated completion is 2026-02-02.

What interventions are being tested in trial NCT05679401?

The interventions under investigation include: Glucocorticoids (DRUG), Imlifidase (DRUG), Plasma exchange (PLEX) (PROCEDURE), Cyclophosphamide (CYC) (DRUG).

Who is sponsoring clinical trial NCT05679401?

This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05679401's enrollment target sits among peer trials

50 1844th of 2000 higher than 141 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-07-11

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05283330 · started 2022-12-22 · Phase 1

    Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

  • NCT05313165 · started 2022-12-22 · NA

    PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

  • NCT05360888 · started 2022-12-22 · NA

    Suicide Intervention for Alaska Native Youth

  • NCT05377125 · started 2022-12-22 · NA

    Neural Mechanisms of Response Inhibition Training for OCRD

Source: ClinicalTrials.gov NCT05679401, the US trial registry maintained by the National Library of Medicine. NCT05679401 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.